🔍
Search Results - ying+chen
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Long-Circulating PSMA-Targeted Phototheranostic Agent
Unmet NeedProstate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. A promising precision cancer treatment known as photodynamic therapy (PDT) offers a way to selectively target prostate cancer cells for destruction. Prostate PDT uses a ligand to attach a light-sensitizing agent known as porphyrin...
Published: 3/14/2025
|
Inventor(s):
Martin Pomper
,
Ronnie Mease
,
Ying Chen
,
Sangeeta Ray
,
Juan Chen
,
Marta Overchuk
,
Gang Zheng
,
Kara Harmatys
Keywords(s):
Cancers
,
Disease Indication
,
Imaging and Sensing Systems
,
In Vivo Medical Imaging
,
Prostate Cancer
,
Target
,
Therapeutic Matter
,
Therapeutics
Category(s):
Clinical and Disease Specializations > Oncology > Prostate Cancer
,
Clinical and Disease Specializations > Men's Health
,
Technology Classifications > Medical Devices > Imaging
,
Technology Classifications > Therapeutic Modalities > Targets
Radiolabeled Triazole Conjugated Ureas (YC-88)
Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate tumors, particularly in castrate-resistant, advanced and metastatic disease. PSMA is also expressed in neovascular endothelium of most solid tumors, such as lung, colon, pancreatic, renal carcinoma and skin melanoma, but not in normal...
Published: 3/13/2025
|
Inventor(s):
Martin Pomper
,
Ronnie Mease
,
Ying Chen
,
Sangeeta Ray
,
Xing Yang
Keywords(s):
Antagonists/Inhibitors
,
Cancers
,
Discovery/Research Tools
,
Disease Indication
,
Imaging Agent
,
Imaging and Sensing Systems
,
In Vivo Medical Imaging
,
Labels/Markers
,
Novel
,
Predicted Novelty
,
Research Reagent
,
Single
,
Small Molecules
,
Targeted Therapy
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Research Tools
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
,
Technology Classifications > Diagnostics > Diagnostic Imaging
New Scaffolds and Multifunctional Intermediates for Imaging PSMA
The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for cancer imaging and therapy. Current PSMA inhibitors based on a urea scaffold have shown good results for imaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) in human subjects. The urea scaffold has...
Published: 3/13/2025
|
Inventor(s):
Martin Pomper
,
Ying Chen
,
Sangeeta Ray
,
Ronnie Mease
,
Xing Yang
,
Georgio Attardo
Keywords(s):
Cancers
,
Disease Indication
,
Imaging Agent
,
Imaging and Sensing Systems
,
Imaging Modality
,
In Vivo Medical Imaging
,
Positron Emission Tomography (PET)
,
Prostate Cancer
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Men's Health
,
Clinical and Disease Specializations > Oncology > Prostate Cancer
,
Technology Classifications > Medical Devices > Imaging
,
Technology Classifications > Medical Devices
,
Clinical and Disease Specializations > Oncology
Prostate-specific Membrane Antigen-targeted Photosensitizers for Photodynamic Therapy
Targeted photodynamic therapy for prostate and solid-tumorsJHU REF: C12525Invention novelty: This invention is a novel drug composition that can target prostate tumors in vivo for use in photodynamic therapy (PDT).Value Proposition:Currently, prostate cancer treatment often requires invasive surgery or treatment with drugs that may cause adverse side-effects....
Published: 3/13/2025
|
Inventor(s):
Ying Chen
,
Ronnie Mease
,
Martin Pomper
Keywords(s):
Cancers
,
Disease Indication
,
Drug Delivery Vehicle
,
Imaging Agent
,
Imaging and Sensing Systems
,
In Vivo Medical Imaging
,
Novel
,
Predicted Novelty
,
Prostate Cancer
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Men's Health
,
Clinical and Disease Specializations > Oncology > Prostate Cancer
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum